|
|
Volumn 94, Issue 9, 2002, Pages 650-651
|
|
Cardiotoxicity concerns prompt data review in breast cancer trial
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRACYCLINE;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
EPIDERMAL GROWTH FACTOR;
MONOCLONAL ANTIBODY;
PACLITAXEL;
TRASTUZUMAB;
BREAST CANCER;
CANCER STAGING;
CARDIOTOXICITY;
CARDIOVASCULAR RISK;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
CONGESTIVE HEART FAILURE;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG ACTIVITY;
DRUG APPROVAL;
DRUG EXPOSURE;
DRUG RESEARCH;
DRUG SAFETY;
DRUG TARGETING;
FEMALE;
GENE OVEREXPRESSION;
HUMAN;
LYMPH NODE METASTASIS;
NOTE;
PATIENT MONITORING;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROGNOSIS;
PROTEIN EXPRESSION;
RANDOMIZED CONTROLLED TRIAL;
RISK BENEFIT ANALYSIS;
TREATMENT OUTCOME;
|
|
EID: 0036566766
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/94.9.650 Document Type: Note |
|
Times cited : (7)
|
|
References (0)
|